Three firms rank highest on access to poor

June 30, 2010 12:10 am | Updated 12:10 am IST

GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.

European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.

The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.

Gilead Sciences and Pfizer rose several ranks from 2008.

Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).

The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed “report cards” on 20 companies.

For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. — New York Times News Service

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.